Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIND-030 (Elanco Animal Health)
- Development stage
- Unknown
- Lead developer
- Elanco
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KIND-030 is a chimeric monoclonal antibody designed for the treatment of Feline Leukemia Virus (FeLV) infection in cats. Developed by Kindred Biosciences and subsequently brought to market by Elanco following its acquisition of Kindred, KIND-030 is the first monoclonal antibody to receive conditional approval from the USDA Center for Veterinary Biologics for this indication. The antibody specifically targets and binds to the FeLV envelope protein, a critical component for viral attachment and entry into feline host cells. By neutralizing the virus, KIND-030 aims to reduce viremia and improve the clinical prognosis for infected cats. It is administered as a single intravenous infusion, providing a targeted therapeutic option where previously only supportive care was available.
- Brand names
- Feline Leukemia Virus Monoclonal Antibody
- Other names
- feline leukemia virus monoclonal antibodyFeLV mAbfeline leukemia monoclonal antibodies
02
Targets
VP2 (Infectious bursal disease virus VP2 protein)
Beyond the preview
Go deeper on KIND-030 (Elanco Animal Health).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIND-030 (Elanco Animal Health).